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Abstract
Purpose Of patients undergoing allogeneic hematopoietic
stem cell transplantation (HSCT), 75 % or more experience
oral mucositis, a painful acute complication that can delay
discharge, interrupt treatment, and threaten life. To evaluate
the efficacy of a supersaturated calcium phosphate rinse
(SCPR), we compared it with customary care—topical
mouth solutions—on measures of severity and consequent
interventions and complications.
Methods In this randomized controlled trial, 40 patients
undergoing allogeneic HSCT were randomized: 20 to SCPR
four times daily and 20 to solutions made with salvia leaf
extract, iodine-povidine, and fluconazole. Treatment extended
from initiation of conditioning treatment until the granulocyte
count was ≥0.2 g/L.Mucositis severity was measured daily by
a hematologist according to a World Health Organization
(WHO) scale and self-assessed by patients. Need for inter-
ventions [analgesics, total parenteral nutrition (TPN), and
granulocyte colony-stimulating factor] and complications
(acute graft-versus-host disease and infections) were also
assessed.
Results In comparison with the control group, the SCPR
group had significantly lower mean measures of WHO oral
toxicity (0.9 vs. 1.8;P00.02), disease course (3.2 vs. 7.1 days;
P00.02), and peak mouth pain (0.85 vs. 1.75; P00.005).
Analgesic need was significantly shorter (1.1 vs. 3.4 days;
P00.047) and the need for TPN significantly lower (0 vs. 6
patients;P00.02; 0 vs. 1.9 mean days; P00.009). Measures of
complications were lower in the SCPR group, but not signifi-
cantly so. Trial limitations include the impracticality of
achieving double blinding with agents so different in appear-
ance and in preadministration preparation.
Conclusions Compared with the control group, the SCPR
group had significantly lower mean measures of oral tox-
icity, peak mouth pain, and disease course duration. These
results warrant confirmation in controlled, multicenter,
randomized trials.
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Introduction
Oral mucositis is the most common acute complication of
hematopoietic stem cell transplantation (HSCT) condition-
ing regimens, and it has been reported to occur in 76–99 %
of patients treated with high-dose chemotherapy and/or total
body irradiation (TBI) before HSCT [1–3]. Mucositis is a
result of both the direct toxic effects of chemotherapy and/or
radiotherapy on mucosa and posttherapeutic neutropenia
predisposing to viral, bacterial, and fungal infections. Muco-
sitis, manifest in erythematous oral cavity ulcerations, can
produce pain, dysphagia, xerostomia, changes in the voice,
and life-threatening sepsis [4]. Affecting all functions of the
mouth—drinking, eating, speaking—and dental and other
mouth care, it affects not only nutrition and quality of life
but also may necessitate total parenteral nutrition (TPN),
demand morphine for pain relief, delay discharge, interrupt
treatment, increase costs, and threaten life. Despite use of
standard oral hygiene regimens, mucositis is one of the most
common causes of severe pain in allogeneic HSCT recipi-
ents [5]. Drugs considered most harmful to oral mucosa
include 5-fluorouracil, methotrexate, doxorubicin, etopo-
side, melphalan, cytarabine, and cyclophosphamide. TBI
may also exert devastating effects on the mucosa [6].
Mucositis can be described by several scales, but the most
common is the World Health Organization (WHO) five-stage
scale: 0—no change; 1—soreness/erythema; 2—erythema,
ulcers, patient can swallow solid food; 3—ulcers, patient
requires liquid diet only; and 4—alimentation impossible [7].
Strategies for preventing mucositis include topical treat-
ment with sodium bicarbonate in saline solution (NaHCO3/
NaCl), chlorhexidine, hydrogen peroxide, and IB-367 (a
naturally occurring antimicrobial agent derived from por-
cine neutrophil peptides) [8–12]. Positive effects have been
obtained with glutamine, interleukin-11, keratinocyte
growth factor (KGF), granulocyte or granulocyte macro-
phage colony-stimulating factor, and amifostine [13–19].
With colleagues, we have previously reported the beneficial
influence of KGF (palifermin) on mucositis and acute graft-
versus-host disease (GVHD) in a retrospective study using a
historical control group [20].
In this study in patients undergoing allogeneic HSCT
after high-dose chemotherapy and radiotherapy, we assessed
the ability of the supersaturated calcium phosphate rinse
(SCPR) Caphosol (EUSA Pharma, Langhorne, PA) to pre-
vent mucositis, reduce its duration and severity, reduce the
need for TPN and analgesics, and improve patient comfort.
Patients and methods
This study was a prospective, randomized, nonblinded con-
trolled trial with 40 consecutive patients undergoing
allogeneic HSCT; half received treatment with the supersat-
urated rinse, and the remaining half received customary care
with topical mouth solutions. Patients enrolled in this study
underwent transplantation in the Department of Hematology
and Bone Marrow Transplantation at the Medical University
of Silesia in Katowice, Poland, in 2009. All patients provid-
ed written informed consent.
Medications were similar between the two groups.
Patients were all on the same immunosuppressive therapy
and were treated with the same antifungal, antibacterial, and
antiviral agents during granulocytopenia. In the case of
infection or suspicion of infection (neutropenic fever of
unknown origin), therapy was chosen across both groups
according to known or suspected microorganism without
significant variation between them.
In this study, we tested the SCPR, a preparation consist-
ing of two separately packaged aqueous solutions (a phos-
phate solution and calcium solution), as a preventive and
treatment for mucositis. When both solutions are combined
in equal volumes, a solution supersaturated with both calci-
um and phosphate ions is formed.
In the treatment group, patients rinsed their mouths four
times daily with the SCPR; in the control group, patients
received customary topical mouth care with extract of salvia
leaves (twice daily), povidone-iodine mouth solution (1 %
water solution of iodide with polyvinylopyrrolidone) once
daily, and fluconazole mouth solution [fluconazole (50 mg),
glycerin (50 mg), vitamin A (10 g), and vitamin E (10 g) with
or without benzocaine (2.5 g)] twice daily. SCPR treatment
was administered from the first day of conditioning until
patients reached the absolute neutrophil count—≥0.2 g/L—a
value that was considered an indication of the beginning of
neutrophil recovery. Patients were stratified by age, prepara-
tive regimen (busulfan, treosulfan, or TBI), and type of trans-
plant donor (related or unrelated) into two equal groups.
Patients self-assessed the level of pain in the mouth and
pharynx using a 0–10 visual analog scale (VAS) and measured
swallowing problems using a 0–5 VAS [21]. The same expe-
rienced hematologist performed a physical examination of the
oral cavity each day throughout the study, ranking cases
according to the WHO scale for grading oral toxic effects of
cancer treatment. Nonparametric Mann–Whitney U tests,
Fisher exact two-tailed tests, and Yates chi-square tests were
used for statistical analysis.
Results
Eighty percent of the patients (32/40) had been diagnosed
with leukemia (acute myeloblastic leukemia, 20; acute lym-
phoblastic leukemia, 10; and chronic myelogenous leuke-
mia, 2; Table 1). The remainder had paroxysmal nocturnal
hemoglobinuria (four), severe aplastic anemia (two),
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myelodysplastic syndrome (one), and osteomyelofibrosis
(one). Almost half of the patients (18) had been on busulfan
(16 mg/kg) and cyclophosphamide (120 mg/kg), 10 had
undergone irradiation (12 Gy) and taken cyclophosphamide
(120 mg/kg), and 10 had received treosulfan (42 g/m2) and
fludarabine (150 mg/m2). One patient had received a higher
dose of cyclophosphamide (200 mg/kg) and another one a
higher dose of cyclophosphamide (160 mg/kg) with a lower
dose of treosulfan (20 mg/m2).
Mucositis was evaluated by an experienced physician
using the WHO scale (Table 2). The mean mucositis score
for the SCPR group was 0.9, but it was twice that (1.8) for the
control group (P00.02). The mean duration of mucositis was
3.2 days for the SCPR group, about half the 7.1 days for the
control group (P00.02). Throughout the course of mucositis,
average mouth pain intensity was significantly lower in the
SCPR group than in the control group (Fig. 1); however,
differences in average pain in the pharynx and with problems
swallowing were not statistically significantly different.
Measures of peak mean pain in the mouth, peak mean pain
in the pharynx, and peak mean swallowing problems were all
lower in the SCPR group (Table 2). Days to an absolute
neutrophil count of >0.5 g/L and to a platelet level >20 g/L
were not significantly different between groups.
Interventions required by mucositis and related com-
plications are reported in Table 2. In the SCPR group,
no patient required TPN, but six in the control group
required TPN. The average duration of TPN was
1.9 days in the control group versus 0 days in the
SCPR group (P00.009). Analgesics administered for
mucositis-related pain (ketoprofen, fentanyl, metamizole,
buprenorphine, and acetaminophen) were required in
three patients in the SCPR group but in nine patients
in the control group. Average analgesic duration was
1.1 days (0–13 days) in the SCPR group, but 3.4 days
(0–18) in the control group (P00.047).
Infectious complications following allogeneic HSCT
were observed in five patients (25 %) in the SCPR group
and in ten (50 %) of the control group. Of the five patients in
the SCPR group, two had bacterial infections (one with
bacteremia), one had a fungal infection, and two had cyto-
megalovirus (CMV) reactivations. Of the ten in the control
group with infectious complications, six had bacterial infec-
tions (three with bacteremia) and four had CMV
reactivations.
GVHD occurred in seven patients in the SCPR group
(GVHD involvement: five, skin only; one, gut only; one,
liver only) but in ten patients in control group (six, skin
only; two, skin and gut; one, skin and liver; one, skin, gut,
and liver). The mean overall degree of acute GVHD was 0.5
vs. 0.9, in favor of the SCPR group. None of these differ-
ences in GVHD between groups was statistically significant.
The supersaturated rinse was well tolerated, no adverse
events were observed, and no patient on it or in the control
group withdrew early.
Discussion
Mucosal damage is a devastating and debilitating complica-
tion of cytotoxic therapy that can have significant adverse
clinical and economic consequences. In this trial, 40 patients
undergoing conditioning for HSCT were randomized to two
groups of 20 each: one group received treatment with SCPR
and the other received routine care with extract of salvia
leaves and antibacterial and antifungal solutions. Patients
underwent SCPR treatments four times daily for an average
of 14.6 (range, 8–21) days posttransplantation. Cases of
mucositis in the treatment group were significantly less
severe, had a significantly shorter duration, were associated
with significantly less mouth pain, and required significant-
ly less pain relief than those in the control group.











Busulfan (16 mg/kg) and
cyclophosphamide (120 mg/kg)
9 9
Total body irradiation (12 Gy)/
cyclophosphamide (120 mg/kg)
5 5






Cyclophosphamide (200 mg/kg) 0 1
Source of transplant
Sibling 5 4
Unrelated donor 15 16
Diagnosis
Acute myeloblastic leukemia 8 12
Acute lymphoblastic leukemia 5 5








a Patients in the control group received topical mouth care with extract
of salvia leaves and povidone-iodine and fluconazole mouth solutions
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The distinguishing feature of SCPR in comparison with
other mouth rinses is the high concentration of Ca2+ and PO4
3−
ions. Theoretically, these highly concentrated ions exert their
beneficial effect by diffusing into intercellular spaces in the
epithelium of mucosa and permeating mucosal lesions. The
Ca2+ ions play a crucial role in the inflammatory process, the
blood-clotting cascade, fibrin production, and tissue repair.
The PO4
3− ions also play an important biochemical role by
facilitating intracellular signalling and regulating the voltage
potential inside the cell, both important for repairing and
protecting damaged mucosal surfaces [22]. The reduction
of acidity in the oral cavity also may play a role in avoiding
mucosa damage, creating a more favorable environment
for opportunistic organisms, and diminishing mucositis
symptoms.
The treatment used by the control group is a standard
rinse that has been used within our center with good results
for a long time. The components—salvia, povidone, and a
fluconazole solution—are generally regarded as unproven.
They were implemented against oral mucositis when it was
formerly conceived as having a bacterial or fungal cause and
are supported by research conducted with very small study
groups, in trials of short duration, and often without true
randomization or controls. They were certainly considered
to be appropriate as controls and to be of no harm.
Salvia extract, which is thought to have antibacterial
properties, was combined in one study with other agents in
Chinese medicine and compared with Dobell’s solution
(sodium borate, sodium bicarbonate, phenol, and glycerol)
in treating 101 patients with advanced nasopharyngeal can-
cer undergoing chemoradiotherapy [23]. Neither statistically
significantly outpaced the other in preset measures, includ-
ing curative effects; however, no negative side effects were
observed, and in a study of 24 patients with head and neck
tumors who were receiving chemoradiotherapy, a mouth-
wash solution containing two species of salvia was associ-
ated with prevention of interruptions of therapy of 3 days or
more [24].
Povidone-iodine, a disinfecting agent, is effective in
decreasing bacterial oral cavity contamination [25, 26]. It
was found in a randomized, prospective trial in 40 patients
Table 2 Measures of mucositis
severity, interventions, and
complications
WHO World Health Organiza-
tion, VAS visual analog scale
aPatients in the control group
received topical mouth care with
extract of salvia leaves and povi-
done-iodine and fluconazole
mouth solutions




Severity (WHO scale) 0.9 (0–4) 1.8 (0–4) 0.02
Duration (days) 3.2 (0–13) 7.1 (0–22) 0.02
Peak mean pain in
mouth (0–10 VAS)
0.85 1.75 0.005






Days to absolute neutrophil
count >0.5 g/L
19 (12–29) 18.25 (12–31) 0.96
Days to platelets>20 g/L 17.26 (9–31) 17.22 (8–34) 0.61
Interventions and complications
Analgesics 3 9 0.085
Duration analgesics used (days) 1.1 (0–13) 3.4 (0–18) 0.047
Total parenteral nutrition (TPN) 0 6 0.02
Duration TPN used (days) 0 1.9 (0–16) 0.009
Granulocyte colony-stimulating factor 0 4 0.106
Acute graft-versus-host disease (aGVHD) 7 9 0.747
Degree of aGVHD 0.5 0.9 0.3























PAIN IN THE MOUTH 
p = 0.005
Fig. 1 Mean ratings of pain in the mouth according to patients’ self-
assessment using a visual analog scale. Values were significantly
different (P00.005) (SCPR supersaturated calcium phosphate rinse)
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undergoing chemoradiotherapy for head and neck disease to
reduce incidence, severity, and duration of oral mucositis
significantly [27]. Two other trials compared povidone with
water or saline and found no statistically significant differ-
ences for any of the outcomes [28, 29]. In 2004, povidone
was listed by a consensus panel as having insufficient evi-
dence to support a guideline [30], and in the panel’s update,
it received no mention [31]. In 2011, a trial of 100 patients
undergoing radiotherapy for head and neck cancer found
benzydamine hydrochloride superior to chlorhexidine as
well as povidone-iodine in delaying the progression of
mucositis and reducing the pain, though differences were
not statistically significant. In the second half of the same
year, manufacturers initiated a recall of povidone-iodine at
the request of the U.S. Food and Drug Administration.
Products distributed nationwide were found to be contami-
nated [32].
Fluconazole, an antifungal agent, is employed to mitigate
Candida oral cavity contamination [25]. It was found in a
2006 quality-of-life study of 63 patients with head and neck
cancer undergoing radiotherapy to have significant benefi-
cial impact as a prophylactic for oral mucositis severity,
including preventing and reducing the presence of Candida
infection [33]. Recent safety reports from the U.S. Food and
Drug Administration have warned of birth defects caused by
systemic use during the first trimester [34]. Reports were
related to much higher doses (400–800 mg/day) than those
topically applied in our study. In very rare cases, fluconazole
has been associated with Stevens–Johnson syndrome [35,
36]. In these instances, doses were topical but two to four
times that applied in this study.
Combined with fluconazole was glycerin, vitamin A,
vitamin E, and sometimes benzocaine. Adverse effects as-
sociated with glycerin include inflammation associated with
a glycerin-containing product [37] and reduced salivary
amylase and pH levels when glycerin was combined with
lemon [38]; however, the citric acid is thought to be respon-
sible for the dramatic reductions. Another trial that included
glycerin in combination with the herb payayor showed the
combination was superior to benzydamine [39]. MuGard, a
product recently approved in the USA and Europe for the
palliation of oral mucositis pain, contains glycerin, and
appeared to cause no known harm in trials; however,
blinded, randomized trials have yet to be done in patients
with head and neck cancer [40].
Both vitamin A and vitamin E have been reported as
beneficial in oral mucositis. Mills et al. [41] demonstrated
that 10 patients receiving vitamin A for chemotherapy- and
radiation-induced oral mucositis developed less severe
mucositis than ten who did not receive vitamin A over 10
to 12 patient-weeks, and researchers studying 80 pediatric
patients in a 5-day study reported that 100 mg of vitamin E
applied twice daily produced a significant benefit over
supplementation [42]. Though not a study in oral mucositis,
a 2010 single-blinded controlled surgical study in 428 pedi-
atric patients found that vitamin E applied before and after
surgery improved wound healing and cosmetic results [43].
Reports of topical vitamin E–induced contact dermatitis are
rare, according to researchers who conducted a literature
review and concluded it should not be removed from prod-
ucts used on the skin [44].
Benzocaine, which was employed with some patients in
this study, is a widely used topical anesthetic. Benzocaine
sprays used to numb the mouth for medical procedures have
been identified by the U.S. Food and Drug Administration
to be responsible for rare but serious adverse effects, includ-
ing death [45]. Methemoglobinemia has resulted in some
cases, and the U.S. Food and Drug Administration said that
more than half of reports that included data on administra-
tion indicated overuse. It has not required safety warning
labeling [45].
Apart from the contaminated products (which were not
used in our trial), reported adverse events when povidone-
iodine is allowed to pool and remain on exposed skin for
long periods of time, overdosing, and other uncommon
adverse events, we have no reason to believe these agents
pose any danger to patients when used and monitored ap-
propriately. The median duration of oral mucositis in the
control group (7.1 days) compares favorably to data
reported by others (7.2–8.0 days) [22, 46, 47], indicating if
anything a competitive course duration.
The SCPR rinse is indicated as an adjunct to normal oral
care in preventing and treating mucositis resulting from
irradiation or high-dose chemotherapy, and it is also indi-
cated for temporary or permanent dryness of the mouth and
oropharynx (hyposalivation and xerostomia), no matter the
cause [48]. Relief of dryness of the oral mucosa in these
conditions is associated with amelioration of pain.
The trend toward lower incidence and severity of acute
GVHD in the SCPR group may be related to decreased
mucosal injury by chemotherapy or radiotherapy in this group
of patients. An additional benefit in the SCPR group was the
absence of the need for GCSF administration, although no
significant differences in time to reconstitute granulocytes and
platelets were observed between the groups.
Limitations of the study include the impracticality of
maintaining a double-blind trial. Iodine solutions (red/
orange color) contrast dramatically with the supersaturated
calcium phosphate solution (colorless), making it difficult to
disguise the differences. Furthermore, the phosphate solu-
tion has to be mixed and requires opening a clear ampule
and a blue ampule immediately before administration.
The findings in this prospective randomized, controlled
study confirm findings in a 1992 report of a double-blind
prospective randomized controlled trial of 95 patients under-
going HSCT [22]. In that trial, SCPR produced statistically
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significantly lower measures of pain duration, disease course
duration, use of analgesics (morphine), and duration of time to
absolute neutrophil recovery than did a fluoride rinse, dem-
onstrating that the SCPR regimen has a significant positive
effect on oral mucositis associated with chemotherapy and
radiotherapy. Under way currently is a randomized, placebo-
controlled, double-blind multisite trial of SCPR by the Child-
ren’s Oncology Group (NCT01305200). The National Cancer
Institute–funded study, which is expected to enroll 200, has as
its primary outcome measure the duration of severe oral
mucositis (WHO grade 3 and 4). One of several secondary
measures will be the evaluation of a new pediatric oral muco-
sitis scale, the Children’s International Mucositis Evaluation
Scale. Findings are eagerly anticipated.
In the trial reported here, the SCPR mouth rinse was
associated with decreased oral toxicity, including lower
peak mouth pain and a shorter disease course, than were
routine oral therapies. In consequence, in comparison with
parallel values in the control group, the SCPR group had
data indicating patient comfort was improved, the trend of
acute GVHD hallmarks was lower, the requirement for TPN
was diminished, and analgesic use was reduced. These
results warrant confirmation in controlled, multicenter, ran-
domized trials. Additional expanded investigations of its use
in larger trial populations and in other settings in which
mucositis occurs should be considered.
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